ROCKET PHARMACEUTICALS INC

During the three months ended March 31, 2025, operating activities used $55.8 million of cash and cash equivalents, primarily resulting from our net loss of $61.3 million offset by net non-cash charges of $11.2 million, including non-cash stock-based compensation expense of $10.3 million, depreciation and amortization expense of $3.0 million, partially offset by accretion of discount on investments of $2.1 million. Changes in our operating assets and liabilities for the three months ended March 31, 2025 included a decrease in accounts payable and accrued expenses of $5.3 million and an increase in our prepaid expenses of $0.5 million.

During the three months ended March 31, 2024, operating activities used $56.9 million of cash and cash equivalents, primarily resulting from our net loss of $62.1 million offset by net non-cash charges of $10.9 million, including non-cash stock-based compensation expense of $10.3 million, depreciation and amortization expense of $2.3 million, partially offset by accretion of discount on investments of $2.8 million and reduction in fair value of warrant liabilities of $1.1 million. Changes in our operating assets and liabilities for the three months ended March 31, 2024, included of a decrease in accounts payable and accrued expenses of $2.4 million, an increase in our prepaid expenses of $1.2 million, and a decrease in other liabilities of $2.1 million.